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Ethambutol (EMB) resistance can evolve through a multistep process, andmutations in the ubiA (Rv3806c) gene appear to be
responsible for high-level EMB resistance inMycobacterium tuberculosis. We evaluated the prevalence of ubiA and embB
(Rv3795) mutations in EMB-resistant strains originating from Africa and South Korea. No differences in embBmutation fre-
quencies were observed between strains from both origins. However, ubiAmutations were present in 45.5% 6.5% of the Afri-
can EMB-resistant isolates but in only 9.5% 1.5% of the South Korean EMB-resistant isolates. The ubiAmutations associated
with EMB resistance were localized to regions encoding the transmembrane domains of the protein, whereas the embBmuta-
tions were localized to regions encoding the extramembrane domains. Larger studies are needed to investigate the causes of in-
creased ubiAmutations as a pathway to high-level EMB resistance in African countries, such as extended EMB usage during tu-
berculosis treatment.
Ethambutol (EMB), a first-line antituberculosis drug, is oftenused in combinationwith other drugs to treat tuberculosis and
prevent the emergence of drug resistance (1). Numerous studies
have shown that mutations in the embCAB operon, particularly
the embB gene, are a major cause of EMB resistance in Mycobac-
terium tuberculosis (2–8). A second set of mutations, which occur
in the ubiA gene, has been associated with EMB resistance in clin-
ical M. tuberculosis isolates (9–11). Mutations in ubiA almost al-
ways occur in EMB-resistant strains that also contain embB mu-
tations, and ubiA appears to have multiplicative effects with embB
mutations onMICs (9). The evolutionary path leading from low-
to high-level EMB resistance has been studied in the laboratory
(9). In these studies, high-level EMB resistance appears to develop
through the stepwise acquisition of mutations in embB, ubiA, and
embC.
In the study described here, we examined the prevalence of
ubiAmutations in isolates from two different geographic regions.
Our results confirm the association between ubiA mutations and
the presence of embB mutations and EMB resistance. We also
demonstrate that the prevalence of these mutations varies by geo-
graphic location, suggesting that local factors may play a role in
the type of mutations which develop as M. tuberculosis strains
evolve to become EMB resistant.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Fifty-four clinical M. tubercu-
losis strains from different geographic regions were selected from a collec-
tion of highly characterized M. tuberculosis isolates established by the
World Health Organization Special Programme for Research and Train-
ing in Tropical Disease (TDR strains; see Table S1 in the supplemental
material) (12). A second set of 39 isolates from the National Masan Hos-
pital in Changwon, South Korea and 41 isolates from the National Refer-
ence Laboratory in Rwanda was also tested (see Table 3). The last two sets
of isolates were part of a drug resistance survey and were cultured from
patient sputum after obtaining informed consent from their institutional
review boards of the respective institutions (13, 14). In this study, M.
tuberculosis strains were cultured at 37°C either in Middlebrook 7H9
broth containing 0.05% (wt/vol) Tween 80 or onMiddlebrook 7H10 agar
supplemented with 0.5% (vol/vol) glycerol, both of which were enriched
with 10% oleic acid-albumin-dextrose-catalase (OADC; Becton Dickin-
son).
DNA isolation, PCR, and DNA sequencing. Genomic DNA was ex-
tracted as described previously, with minor modifications (15, 16). To
amplify DNA fragments for DNA sequencing, the PCR was performed
using a mix containing 1 ng of genomic DNA, 5 pmol of each primer, 200
M deoxynucleoside triphosphates, 1 PCR buffer, and 1 U of high-
fidelity Pfx Taq polymerase (Invitrogen). All PCR products were purified
using a gel extraction kit (Qiagen). Direct bidirectional Sanger sequencing
of the embB and ubiA genes was performed with a BigDye Terminator kit
and analyzed with an ABI 3100 genetic analyzer (Applied Biosystems). All
primer sequences used in this study are described in Table 1.
MIC testing and DST. The EMBMICs of the TDR strains were deter-
mined in this study using the standard radiometric Bactec 460TBmethod
(Becton Dickinson and Company, Sparks, MD) following the manufac-
turer’s instructions with minor modifications (4). Each strain was tested
against serial 2-fold increases in the antibiotic concentration. To confirm
the results obtained by the Bactec method, 5  103 CFU from the same
Received 16 December 2015 Returned for modification 10 January 2016
Accepted 12 April 2016
Accepted manuscript posted online 2 May 2016
Citation Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL,
German S, Cho E, Lee J-I, Cho S-N, Kim CT, Alland D, Safi H. 2016. Geographic
differences in the contribution of ubiA mutations to high-level ethambutol
resistance inMycobacterium tuberculosis. Antimicrob Agents Chemother
60:4101–4105. doi:10.1128/AAC.03002-15.
Address correspondence to Hassan Safi, safiha@njms.rutgers.edu.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.03002-15.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
crossmark
July 2016 Volume 60 Number 7 aac.asm.org 4101Antimicrobial Agents and Chemotherapy
inoculum was also spotted onto plates of 7H10 medium containing serial
increases in the concentrations of EMB. The plates were incubated at 37°C
for 2 to 3 weeks, and the MICs were determined to be the antibiotic
concentration that inhibited growth compared to the growth of the 1/100
dilution on antibiotic-free 7H10 medium. The MICs determined by the
Bactec method were not significantly different from those determined by
the agar method. Drug susceptibility testing (DST) for determination of
the EMB susceptibilities of the clinical strains from Rwanda and South
Korea was performed previously by local clinical laboratories using the
mycobacterial growth indicator tube (MGIT) method with a cutoff of 5
g/ml, as indicated in the manufacturer’s package inserts, and/or by the
agar proportionmethod on Lowenstein-Jensenmediumwith a cutoff of 2
g/ml, as described previously (17).
Statistical analysis. For each gene, embB and ubiA, the associations
between mutation status (presence, absence) and both the EMB MIC
category and the geographic origin of the strain (Africa, South Korea)
were assessed. Either the Pearson chi-square test or Fisher’s exact test, if
the expected sample countswere small, was used. The association between
the frequency of embB mutations and ubiA mutations among all strains
was assessed by McNemar’s test for paired samples. A linear trend be-
tween mutations in each of the embB and ubiA genes and the EMB MIC
was assessed using the exact Cochran-Armitage test for trend. All statisti-
cal tests were performed at a significance level of alpha equal to 0.05. All
statistical analyses were performed using SAS (version 9.4) software (SAS
Institute, Cary, NC).
Nucleotide sequence accession numbers. In this study, we identified
six new mutations in the ubiA gene, and the sequences were deposited in
the GenBank database under accession numbers KX021867 for UbiA
A38V, KX021868 for UbiA V55G, KX021869 for UbiA V148A, KX021870
for UbiA S173A, KX021871 for UbiA V229G, and KX021872 for UbiA
S173A/A278V.
RESULTS
Examination of ubiA and embB genotypes in M. tuberculosis
TDR strains isolated in South Korea and in African countries.
Wemeasured the EMBMICs of 54M. tuberculosis clinical strains
isolated in South Korea and in Africa selected from the TDR col-
lection (see Table S1 in the supplemental material) and sequenced
the embB and ubiA genes of each of these strains. We then classi-
fied each strain into one of three EMBMIC categories: susceptible
(MIC, 2 g/ml), low-level resistant (MIC, 4 to 16 g/ml), and
high-level resistant (MIC, 32 g/ml) (Table 2). None of the sus-
ceptible strains contained a mutation in either embB or ubiA.
However, embB mutations were identified in many of the low-
level and high-level EMB-resistant strains. No differences in embB
mutation frequency were observed between strains of African or-
igin (10/10 [100%] high-level resistant strains and 9/11 [82%]
low-level resistant strains) and strains of South Korean origin (5/5
[100%] high-level resistant strains and 17/23 [74%] low-level re-
sistant strains) (P 1.00). Mutations in ubiA were also identified
in low-level and high-level EMB-resistant strains. Contrary to the
findings for the embB mutations, ubiA mutations occurred more
frequently in the strains of African origin (8/10 [80%] high-level
resistant strains and 3/11 [27%] low-level resistant strains) than in
strains of South Korean origin (2/5 [40%] high-level resistant
strains and 1/23 [4%] low-level resistant strains) (Table 2). Com-
bining all EMB-resistant strains (MICs, 2 g/ml), ubiA muta-
tions were significantly more prevalent in strains of African origin
(11/21, 52%) than in strains of South Korean origin (3/28, 11%)
(P 0.001). Our results also confirmed thatmutations in ubiA are
TABLE 1 Primers used for amplification and sequencing
Gene (Rv designation) Size (bp) Primer Sequence Product location
ubiA (Rv3806c) 909 F-ubiAa ACGTTGAGCTTGAGGCTAGC 116 to15
R-ubiAa CGCTGTCGCGAATACTGCT
Fin-ubiAseqb GGTAGACGACCATTACCAGC NAc
Rin-ubiAseqb GGTACTGGGAGTGACATCGC NA
embB (Rv3795) 3297 F1-embBa ATCGGTGGAGCAGTACCA 117 to 877
R1-embBa ATGACATGCCAGAGCAGG
F2-embBa CACCGTCGTCGCACTGAT 683 to 1675
R2-embBa CGCAACATGATGAACACCG
F3-embBa CGTGGTATACCGAGAACCTG 1549 to82
R3-embBa CATACCGAGCAGCATAGGAG
Fin3-embBseqb CGCATTCACACTGGGTGTGC NA
Rin3-embBseqb GGCAGGATGAGGTAGTAG NA
a Primers used for PCR and sequencing.
b Primers used only for sequencing.
c NA, not applicable.
TABLE 2 Distribution of embB and ubiA mutants among TDR strains classified by EMB MIC and geographic origin
EMB MIC (g/ml)
No. of MTa/no. of strains tested (%b)
embB ubiA
Africa South Korea Total Africa South Korea Total
32 10/10 (100) 5/5 (100) 15/15 (100) 8/10 (80) 2/5 (40) 10/15 (67)
4–16 9/11 (82) 17/23 (74) 26/34 (76) 3/11 (27) 1/23 (4) 4/34 (12)
2 0/3 (0) 0/2 (0) 0/5 (0) 0/3 (0) 0/2 (0) 0/5 (0)
a MT, mutant.
b Percentage of mutants.
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associatedwith high-level EMB resistance (10/15 [67%]high-level
resistant strains versus 4/34 [12%] low-level resistant strains; P
0.001), supporting the findings of a previous study (9). All the
ubiAmutations occurred in strains that also had embBmutations.
ubiA genotypes ofM. tuberculosis EMB-resistant strains iso-
lated in clinical laboratories of hospitals in Rwanda and in
South Korea. The ubiA mutation frequencies in African versus
South Korean strains were then investigated by use of a second
independent set of EMB-resistant strains obtained from Rwanda
and South Korea. Because of the similar embBmutation frequen-
cies described in African and South Korean EMB-resistant TDR
strains, only the ubiA gene from this second set of strains was
sequenced. Significant differences in ubiA mutation frequencies
similar to those seen in the first set of strains tested were observed.
Mutations in ubiA were detected in 16/41 (39%) EMB-resistant
Rwandese isolates and 3/39 (8%) EMB-resistant South Korean
isolates (P 0.001) (Table 3). Three DNA samples from Rwanda
had a mixture of wild-type and mutant ubiA sequences, and one
DNA sample from South Korea had a double mutation in ubiA
(Table 3).
Mutations in ubiA that are associated with EMB resistance
are localized in the region encoding the transmembrane do-
mains of the protein.TheubiAmutations from this study and our
previously published study provide the largest collection of ubiA
mutations so far reported in M. tuberculosis (9). We previously
identified two mutations, R76R and E149D, to be phylogenetic
markers associated with ancestral M. tuberculosis strains (lineage
1) (9, 18). Indeed, both the R76R and E149D mutations are pres-
ent in the published genome sequences of M. bovis species, M.
africanum, andM. canettii strains in GenBank (ftp://ftp.ncbi.nlm
.nih.gov/genomes/all) (see Table S2 in the supplemental mate-
rial).We examined the location of the ubiAmutations in relation-
ship to the predicted secondary structure of the UbiA protein.
Computer models have predicted that UbiA and Emb are integral
membrane proteins consisting of cytoplasmic loops, transmem-
brane domains, and extracytoplasmic loops (2, 3, 19). UbiA is
predicted to be an -helical protein with nine transmembrane
domains and no large carboxy-terminal region (19). After elimi-
nating the R76R and E149D mutations and other synonymous
mutations andmutations found in susceptible clinical isolates, we
found that the amino acid changes in the UbiA protein associated
with EMB resistance were almost exclusively located in the pre-
dicted transmembrane domains of the protein (Fig. 1). Interest-
ingly, the location of the UbiA resistance-associated mutations
contrasted markedly with the predicted location of mutations as-
sociated with EMB resistance in the EmbB protein. EmbB is pre-
dicted to be an-helical protein with 11 transmembrane domains
and a carboxy-terminal region of approximately 375 amino acids
(3). In contrast to UbiA, the amino acids of EmbB associated with
EMB resistance are predicted to be located in the extracytoplasmic
loops of the membrane (3). While the contrasting locations of the
UbiA and EmbB mutations associated with EMB resistance are
striking, the functional significance of this difference is unclear.
DISCUSSION
This study confirms the previously documented association be-
tween ubiAmutations and EMB resistance, particularly with high-
level EMB resistance (9). We found that ubiA mutations are al-
ways found together with embB mutations in EMB-resistant
strains but that embBmutations can occur in the absence of ubiA
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mutations. This observation suggests that mutations occur in
embB as the first step in the evolution of EMB resistance and that
ubiAmutations occur as secondary mutations, usually in associa-
tion with high-level EMB resistance.
We have previously identified the association of the R76R and
E149D ubiA mutations with lineage 1 of M. tuberculosis and not
with EMB resistance (9). It is well reported that the changes in
resistance genes should be evaluated when developing molecular
diagnostic assays and managing treatment decisions (20). The
V188A, A237V, R240C, and A249G mutations in ubiA have been
conclusively shown, using allelic exchange studies, to cause EMB re-
sistance (9); and using overexpression studies, K174T, W175C, and
F176L mutations have been strongly implicated as a cause of EMB
resistance (10). Thus, similar studies are needed to evaluate the con-
tribution of other ubiA mutations in EMB resistance, further refine
the association of all common ubiAmutations and EMB resistance,
and improve genotypic drug resistance testing (20).
We found that ubiA mutations occurred more frequently in a
collection of EMB-resistant isolates of African origin than a col-
lection of EMB-resistant isolates of South Korean origin. This ob-
servation was confirmed with a second set of representative EMB-
resistant isolates from Rwanda and South Korea. The reasons
behind these regional differences in ubiA mutations remain un-
clear. It could be due to regional variations inM. tuberculosis strain
types. Indeed, virtually all M. tuberculosis strains isolated from
South Korea are members of the Beijing family of lineage 2 (21,
22), while most strains in Africa are members of lineage 1 or 3,
with the T2 family being the most predominant genotype in
Rwanda (23–26). Alternatively, variations in treatment practices
among geographic regions could induce different resistance mu-
tation profiles among EMB-resistant isolates. Standardized anti-
tuberculosis regimens in Rwanda use EMB for both the initial
treatment and retreatment of tuberculosis, and drug susceptibility
tests (DSTs) were not used to tailor treatments during the sam-
pling period. In the absence of routine DSTs, clinicians may con-
tinue to use EMB even in EMB-resistant cases, potentially leading to
thedevelopmentof secondarymutations inubiAandhigh-levelEMB
resistance. In contrast, clinicians in SouthKorea typically adjust their
treatment regimens according to the results of DSTs that are per-
formed at the start of treatment. These adjustments may prevent
EMB-resistant isolates from acquiring additional EMB resistance
mutations, including ones in ubiA. Routine DST is thought to im-
prove treatment outcomes and to prevent the acquisition of resis-
tance to new drugs (27). Our results also suggest that themore wide-
spreaduseofDSTcouldprevent the further evolutionof resistance to
a drug to which anM. tuberculosis strain is already resistant.
Our large panel of mutations permitted us to map UbiA resis-
tance mutations to several transmembrane domains. The active
site of the UbiA protein has been shown to be in the N-terminal
region located in cytoplasmic loops II and IV (19). Thus, it is not
clear how transmembrane mutations could lead to increased de-
caprenylphosphoryl-	-D-arabinose production and EMB resis-
tance, as previously shown (9). One possibility is that UbiA is
involved in a large enzyme complex with Emb proteins and other
arabinan biosynthetic pathway components and thatmutations in
the transmembrane domains of UbiA could affect the stability or
efficacy of this complex.
This study suggests that EMB resistance continues to evolve in
isolates that are already EMB resistant through the acquisition of
additionalmutations. Our results also suggest thatmolecular tests
for drug resistance should be implemented in antituberculosis
health programs throughout the world to reduce the misuse of
antimicrobials and to control the emergence of resistant strains.
More clinical studies are needed to determine the contribution of
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embCAB, ubiA, and aftAmutations to the evolution of EMB resis-
tance in different geographic regions. These future studies should
help to identify biomarkers for low-level and high-level EMB re-
sistance, which will improve treatment decisions and prevent the
emergence of multidrug-resistant organisms.
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